Astrazeneca — Shareholder Meeting (2005)

5 slides from Astrazeneca's shareholder meeting presentation, 2005

Slide 1: Tom McKillop AGM Annual Business Review
Tom McKillop AGM ANNUAL BUSINESS REVIEW Headline results FY 04 2004 2003 Actual CER $m $m growth growth Sales 21,426 18,849 +14% +9% Operating profit 4,770 4,111 +16% +15% EPS (pre-excep) $2.11 $1.78 +19% +18% EPS $2.28 $1.78 +28% +27% Dividends $0.94 $0.795 1
Slide 2: Key growth products
Key growth products 2004 Sales Growth $m (CER) Nexium 3,883 +15% Seroquel 2,027 +33% Arimidex 811 +48% Casodex 1012 +11% Symbicort 797 +32% Crestor 908 n/m Iressa 389 +65% Headline results 1Q 05 2005 2004 Actual CER $m $m growth growth Sales 5,743 5,074 +13% +9% Operating profit 1,453 1,052 +38% +34
Slide 3: Share price performance
Share price performance 110 105 100 95 90 85 80 75 70 65 60 May-04 Dec-04 Jan-04 Oct-04 Feb-05 Apr-05 Mar-04 Jul-04 AstraZeneca Major international pharmaceutical companies* 3
Slide 4: Strong momentum of growth portfolio
Strong momentum of growth portfolio 12,000 10,000 8,000 $m 6,000 4,000 2,000 0 Q1 00 MAT Q1 01 MAT Q1 02 MAT Q1 03 MAT Q1 04 MAT Q1 05 MAT Seroquel Ar imidex Nexium Symbic ort Cr es tor Atac and Cas odex Zomig Faslodex Ires sa 4
Slide 5: Tom McKillop AGM Annual Business Review
Tom McKillop AGM ANNUAL BUSINESS REVIEW 5